Department of Pathology, University of Udine, Udine, Italy.
Department of Medicine (DIMED), University of Padua, Padua, Italy.
Pathol Res Pract. 2023 Mar;243:154366. doi: 10.1016/j.prp.2023.154366. Epub 2023 Feb 10.
Approximately 15 % of colorectal adenocarcinomas (CRCs) are characterized by an altered expression of DNA mismatch repair (MMR) proteins (i.e. MMR deficiency [MMRd]). Lymph node ratio (LNR) represents one of the most important prognostic markers in non-advanced CRCs. No significant data are available regarding LNR distribution depending on MMR status.
The aim of the present work was to compare pathological and clinical characteristics of MMRd tumors versus MMR proficient (MMRp) cases. Particular attention was paid to how these molecular sub-groups relate to the LNR.
A mono-Institutional series of 1037 consecutive surgically treated stage I-IV CRCs were retrospectively selected and data were obtained from pathological reports. Cases were characterized for MMR/MSI status by means of immunohistochemistry or for microsatellite instability (MSI) analysis.
MMRd/MSI tumors (n = 194; 18.7 %) showed significant differences in comparison to MMRp lesions for sex (female prevalence 50.5 % vs 40.7 %; p = 0.013), age (74.2 vs 69.2; p < 0.001), location (right side; p < 0.001), diameter (larger than MMRp; p < 0.001), growth pattern (expansive pattern of growth; p < 0.001), peri- (p = 0.0002) and intra-neoplastic (p = 0.0018) inflammatory infiltrate, presence of perineural invasion (p < 0.001), stage (lower stage at presentation; p < 0.001), grade (higher prevalence of high-grade tumors; p < 0.001), and LNR (lower; p < 0.001).
MMRd/MSI tumors are a distinct molecular CRC subtype characterized by a significantly lower LNR in comparison to MMRp lesions. These data further support the prognostic impact of MMRd/MSI status in early-stage CRCs.
约 15%的结直肠腺癌(CRC)表现为 DNA 错配修复(MMR)蛋白表达改变(即 MMR 缺陷[MMRd])。淋巴结比率(LNR)是非晚期 CRC 最重要的预后标志物之一。关于 LNR 分布与 MMR 状态的关系尚无显著数据。
本研究旨在比较 MMRd 肿瘤与 MMR 功能完整(MMRp)病例的病理和临床特征。特别关注这些分子亚群与 LNR 的关系。
回顾性选择了 1037 例连续接受手术治疗的 I-IV 期 CRC 单机构系列病例,并从病理报告中获得数据。通过免疫组织化学或微卫星不稳定性(MSI)分析对病例进行 MMR/MSI 状态特征分析。
与 MMRp 病变相比,MMRd/MSI 肿瘤(n=194;18.7%)在性别(女性患病率 50.5% vs. 40.7%;p=0.013)、年龄(74.2 岁 vs. 69.2 岁;p<0.001)、部位(右侧;p<0.001)、直径(大于 MMRp;p<0.001)、生长模式(扩张性生长模式;p<0.001)、肿瘤周围(p=0.0002)和肿瘤内(p=0.0018)炎症浸润、神经周围侵犯(p<0.001)、分期(较低的原发分期;p<0.001)、分级(高分级肿瘤的更高患病率;p<0.001)和 LNR(较低;p<0.001)方面存在显著差异。
MMRd/MSI 肿瘤是一种独特的分子 CRC 亚型,与 MMRp 病变相比,其 LNR 显著降低。这些数据进一步支持 MMRd/MSI 状态在早期 CRC 中的预后影响。